What have we learnt from past failures in Alzheimer’s disease drug discovery?
Open accessAbstract
Alzheimer’s disease (AD) is a priority health problem in advanced societies and in many emerging and developing countries, with high cost for public health services, an overload on the economy of f...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Factors contributing to suboptimal performance of AD drugs include selection of drug targets, use of biomarkers and animal models in experimental designs, late treatment initiation, dose-dependent side effects, challenges in BBB permeability, and heterogeneous presentation of patients.
“Factors contributing to the suboptimal performance of drugs include the selection of drug targets, the use of biomarkers and animal models in experimental designs, and other issues such as late treatment initiation, dose-dependent side effects, challenges in BBB permeability, and the heterogeneous presentation of patients.182,479,480”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works
Diagnosis and Management of Dementia: Review
Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) · JAMA · doi:10.1001/jama.2019.4782 · Cited by 1,451 · see citing works
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242 · see citing works
Neurotoxic reactive astrocytes induce cell death via saturated lipids
Guttenplan, K. A., Weigel, M. K., Prakash, P., Wijewardhane, P. R., Hasel, P., Rufen-Blanchette, U., Münch, A. E., Blum, J. A., Fine, J., Neal, M. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03960-y · Cited by 578 · see citing works
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557 · see citing works
Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524 · see citing works
Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354 · see citing works
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242 · see citing works
Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189 · see citing works
The economic cost of dementia: A systematic review
Cantarero, D., Lanza‐León, P., Blázquez‐Fernández, C., Sánchez‐Juan, P., & Sarabia‐Cobo, C. (2019) · Dementia · doi:10.1177/1471301219837776 · Cited by 143 · see citing works
The role of pharmacogenomics in adverse drug reactions
Cacabelos, R., Cacabelos, N., & Carril, J. C. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597706 · Cited by 113 · see citing works
Self-citationThe estimated cost of dementia in Japan, the most aged society in the world
Sado, M., Ninomiya, A., Shikimoto, R., Ikeda, B., Baba, T., Yoshimura, K., & Mimura, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206508 · Cited by 89 · see citing works
Cacabelos, R., Carril, J. C., Cacabelos, N., Kazantsev, A. G., Vostrov, A. A., Corzo, L., Cacabelos, P., & Goldgaber, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051249 · Cited by 87 · see citing works
Self-citationPharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 85 · see citing works
Self-citationHave there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Cacabelos, R. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1457645 · Cited by 72 · see citing works
Self-citationMukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66 · see citing works
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Lalli, G., Schott, J. M., Hardy, J., & Strooper, B. D. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114781 · Cited by 66 · see citing works
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 61 · see citing works
Self-citationHow plausible is an Alzheimer’s disease vaccine?
Cacabelos, R. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1667329 · Cited by 54 · cited 1× · see citing works
“scavengers, β-sheet breakers, δ-secretase inhibitors, αsecretase modulators, and Notch inhibitors [15,16].”
Self-citationCacabelos, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779700 · Cited by 50 · see citing works
Self-citationCacabelos, R., Carril, J. C., Sanmartín, A., & Cacabelos, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00006-1 · Cited by 35 · see citing works
Self-citationPharmacogenomics of drugs used to treat brain disorders
Cacabelos, R. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1738217 · Cited by 24 · see citing works
Self-citationEpigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders
Cacabelos, R., Cacabelos, P., & Carril, J. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00038-3 · Cited by 18 · see citing works
Self-citationPopulation-level pharmacogenomics for precision drug development in dementia
Cacabelos, R. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1468218 · Cited by 16 · see citing works
Self-citationCacabelos, R., Carril, J. C., Corzo, L., Fernández‐Novoa, L., Pego, R., Cacabelos, N., Cacabelos, P., Alcaraz, M., Tellado, I., & Naidoo, V. (2021) · Pharmaceuticals · doi:10.3390/ph14040366 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 5
- Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer's Disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics. 2016;1:151-209.
- Cacabelos R, Goldgaber D, Vostrov A, et al. APOE-TOMM40 in the Pharmacogenomics of demetia. J Pharmacogen Pharmacoprot. 2014;5:135.
- Cacabelos R. Pharmacogenomic of drugs to treat brain disorders. Exp Rev Precis Med Drug Dev. 2020;5(3):181-234.
- VandeVrede L, Gibbs DM, Koestler M, et al. Symptomatic amy- loid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement. 2020;12(1): e12101.
- Cacabelos R, Carrera I, Martínez-Iglesias O, et al. What is the gold standard model for Alzheimer's disease drug discovery and development? Expert Opin Drug Discov. 2021;25:1-26.
Cited by
Sorted by citations
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works
Fominykh, V., Shadrin, A. A., Jaholkowski, P. P., Bahrami, S., Athanasiu, L., Wightman, D. P., Uffelmann, E., Posthuma, D., Selbæk, G., Dale, A. M., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106174 · Cited by 28 · see citing works
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, I., Corzo, L., & Naidoo, V. (2024) · Life · doi:10.3390/life14121555 · Cited by 31 · see citing works
Self-citationPharmacogenetics of Anxiety and Depression in Alzheimer’s Disease
Cacabelos, R., Carril, J. C., Corzo, L., Pego, R., Cacabelos, N., Alcaraz, M., Muñiz, A., Martínez-Iglesias, O. A., & Naidoo, V. (2023) · Pharmacogenomics · doi:10.2217/pgs-2022-0137 · Cited by 27 · see citing works
Self-citationPersonalized Management and Treatment of Alzheimer’s Disease
Cacabelos, R., Naidoo, V., Martínez-Iglesias, O. A., Corzo, L., Cacabelos, N., Pego, R., & Carril, J. C. (2022) · Life · doi:10.3390/life12030460 · Cited by 19 · see citing works
Self-citationMartínez-Iglesias, O. A., Naidoo, V., Carrera, I., Corzo, L., & Cacabelos, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112447 · Cited by 18 · see citing works
Self-citationSingh, S. K., Kumar, A., Singh, R. B., Ghosh, P., & Bajad, N. G. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221026091010 · Cited by 14 · see citing works
Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review
Islam, M. R., Rabbi, M. A., Hossain, T., Sultana, S., & Uddin, S. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00360 · Cited by 10 · see citing works
Exploring perceptions of travel-eligible individuals with dementia and hotel operators
Wen, J., Zheng, D., Jiang, Y., Hou, H., Phau, I., & Wang, W. (2023) · Anatolia · doi:10.1080/13032917.2023.2282050 · Cited by 9 · see citing works
Why people hesitate about dementia screening: A systematic review and meta-analysis
Jin, J., Li, B. J., & Theng, Y. L. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118360 · Cited by 7 · see citing works
The complex web of membrane contact sites in brain aging and neurodegeneration
Tehran, D. A., & Pizzo, P. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05830-6 · Cited by 7 · see citing works
Thành, N. Đ., Hai, D. S., Toán, V. N., Van, H. T. K., Giang, N. T. K., & Tri, N. M. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202300557 · Cited by 7 · see citing works
Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data
Sáez-Atiénzar, S., Souza, C. D. S., Chia, R., Beal, S. N., Lorenzini, I., Huang, R., Levy, J., Burciu, C., Ding, J., Gibbs, J. R., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100679 · Cited by 6 · see citing works
Yue, C., Chen, B., Pan, F., Wang, Z., Yu, H., Liu, G., Li, W., Wang, R., & Tang, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00172 · Cited by 5 · see citing works
Lu, X., Sun, W., Leng, L., Yang, Y., Gong, S., Zou, Q., Niu, H., & Wei, C. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.70061 · Cited by 3 · see citing works
Cacabelos, R. (2022) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/1875692119666220603154831 · Cited by 3 · see citing works
Self-citationThe impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, J., Rodríguez, D., & Naidoo, V. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2433626 · Cited by 4 · see citing works
Self-citationRahimpour, A., Shahbazi, B., & Mafakher, L. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2313166
Mechanism-Free Repurposing of Drugs For C9orf72-related ALS/FTD Using Large-Scale Genomic DataPreprint
Sáez-Atiénzar, S., Souza, C. D. S., Chia, R., Beal, S. N., Lorenzini, I., Huang, R., Levy, J., Burciu, C., Ding, J., Gibbs, J. R., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4783236
Mechanism-Free Repurposing of Drugs For C9orf72-Related ALS/FTD Using Large-Scale Genomic DataPreprint
Sáez-Atiénzar, S., Souza, C. D. S., Chia, R., Beal, S. N., Lorenzini, I., Huang, R., Levy, J., Burciu, C., Ding, J., Gibbs, J. R., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4890101
Gui-hua, X., Song, Y., Yang, B., Yan, J., Wang, Y., Yin, H., Zhang, X., Xu, G., & Bai, Y. (2026) · JMIR Human Factors · doi:10.2196/91657
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
- Authors
- Cacabelos, R.
- Affiliations
- EuroEspes Biomedical Research Center (ES)
- Corresponding author
- Cacabelos, Ramón
- ORCID
- Cacabelos, Ramón
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2022-02-06
- Volume
- 17
- Issue
- 4
- Pages
- 309-323
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W4210874196
- Cited by
- 22
- References
- 28
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 3 · 2022: 4
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Opinion on Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- manuscript was not funded
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, drug discovery, drug development failure, clinical trial failure, translational research
- MeSH terms
- Alzheimer Disease, Humans, Pharmacogenetics, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
